Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Penn study may lead the way for first medication to treat cocaine addiction


Breakout data suggests a wake-promoting agent promotes cocaine abstinence

Cocaine dependence is a major public health problem affecting thousands of people around the globe. Despite years of active research there are still no approved medications for the treatment of this life-shattering addiction. Researchers are now hopeful that may soon change based on the results of a controlled study done at the University of Pennsylvania School of Medicine. The study’s findings can be found in the January issue of Journal of Neuropsychopharmacology and on-line at Penn investigators have identified Modafinil – a wake-promoting agent approved for the treatment of narcolepsy – as a possible medicinal treatment for cocaine dependence. In a double-blind, placebo-controlled trial, researchers found Modafinil promoted cocaine abstinence in treatment-seeking outpatients. Modafinil was also shown to blunt cocaine-induced euphoria in a prior study conducted by the same research group, perhaps explaining its clinical advantage. "If confirmed by further investigation, this could be the breakthrough we have been waiting for," says Charles Dackis, MD, Chief of Psychiatry at the University of Pennsylvania Medical Center – Presbyterian, and the study’s principal investigator.

"Cocaine is capable of destroying not only the lives of those addicted, but also those around them," adds Dackis. "An effective treatment for cocaine addiction would help those most vulnerable in our society to overpower their addiction and regain control in their lives." The trial was conducted at Penn’s Treatment Research Center between 2002 and 2003. It involved a sample of 62 cocaine-dependent patients (aged 25-63) free of significant medical and psychiatric conditions. All participants were from the Philadelphia area. After initial screenings, eligible patients were randomized to a single morning dose of Modafinil (400 mg), or matching placebo tablets, that was continued for eight weeks along with twice-weekly cognitive behavioral therapy (CBT). Thirty participants were treated with Modafinil; and 32 were given placebo.

The primary efficacy measure was cocaine abstinence, measured by urine toxicity testing. Secondary measures were craving, cocaine withdrawal, retention, and adverse events. Modafinil-treated patients provided significantly more cocaine-negative urine samples over the eight-week period than those given placebo, and were more likely to achieve protracted cocaine abstinence.

Along with this finding, Penn researchers also discovered that there were no serious adverse events in those treated with Modafinil, and none of the patients failed to complete the study as a result of any side effects. "These preliminary results are very promising and three larger studies of modafinil for cocaine dependence are currently underway, including one at Penn," adds Dr. Dackis.

This study was funded by research grants from the National Institute of Drug Abuse. Cephalon Inc. provided Modafinil and matched placebo tablets, but had no participation in the design or implementation of the trial. Other Penn researchers contributing to the study are Kyle M. Kampman, MD, Kevin G. Lynch, PhD, Helen M. Pettinati, PhD, and Charles O’Brien, MD, PhD.

Ed Federico | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>